ACSL4 and cancer: ACSL4 deletion or treatment with liproxstatin-1, an inhibitor of ferroptosis, significantly reduced 4-hydroxynonenal (4-HNE) levels, while the level of 4-HNE in esophageal cancer tissues after radiotherapy was significantly associated with better clinical prognosis of cancer patients (257).